Graham Capital Management L.P. Makes New $513,000 Investment in Evolent Health, Inc. (NYSE:EVH)

Graham Capital Management L.P. bought a new stake in Evolent Health, Inc. (NYSE:EVH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 45,594 shares of the technology company's stock, valued at approximately $513,000.

Several other institutional investors have also recently added to or reduced their stakes in EVH. Summit Creek Advisors LLC raised its holdings in shares of Evolent Health by 0.8% in the 4th quarter. Summit Creek Advisors LLC now owns 202,114 shares of the technology company's stock valued at $2,274,000 after buying an additional 1,636 shares during the period. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Evolent Health during the fourth quarter worth about $26,000. Parkside Financial Bank & Trust boosted its stake in shares of Evolent Health by 90.7% in the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after purchasing an additional 2,358 shares during the period. Johnson Investment Counsel Inc. grew its holdings in shares of Evolent Health by 28.0% in the fourth quarter. Johnson Investment Counsel Inc. now owns 11,607 shares of the technology company's stock valued at $131,000 after purchasing an additional 2,542 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in Evolent Health during the 4th quarter worth approximately $31,000.

Evolent Health Stock Performance

Shares of EVH stock traded down $0.20 during trading hours on Monday, hitting $8.63. The stock had a trading volume of 968,280 shares, compared to its average volume of 2,399,972. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market capitalization of $1.01 billion, a PE ratio of -10.52 and a beta of 1.04. Evolent Health, Inc. has a twelve month low of $8.35 and a twelve month high of $33.63. The stock's 50 day moving average is $9.60 and its 200 day moving average is $10.96.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The technology company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.08 by ($0.02). The business had revenue of $483.65 million during the quarter, compared to analyst estimates of $460.15 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The company's revenue for the quarter was down 24.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.34 earnings per share. As a group, research analysts forecast that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Activity

In other Evolent Health news, Director Diane Holder bought 2,735 shares of the business's stock in a transaction on Thursday, March 6th. The stock was bought at an average price of $9.33 per share, for a total transaction of $25,517.55. Following the completion of the transaction, the director now owns 70,584 shares in the company, valued at approximately $658,548.72. The trade was a 4.03% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brendan B. Springstubb purchased 5,000 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were bought at an average cost of $8.75 per share, for a total transaction of $43,750.00. Following the purchase, the director now owns 11,842 shares of the company's stock, valued at $103,617.50. This trade represents a 73.08% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 74,000 shares of company stock valued at $666,315 over the last quarter. Corporate insiders own 1.40% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on EVH shares. Truist Financial dropped their price target on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Piper Sandler reiterated an "overweight" rating and issued a $16.00 price objective (down from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. Canaccord Genuity Group reduced their price objective on Evolent Health from $23.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. JPMorgan Chase & Co. decreased their price objective on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research report on Monday, March 10th. Finally, Stephens decreased their price target on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a report on Tuesday, January 21st. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $17.79.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.